Hear insights from a group of physicians that have recently participated in primary market research via TDIs, IDIs, FGDs or on-line surveys and interviews.
So how can researchers continue to leverage the emotional depth of media assets without running afoul of strict privacy controls? One answer is Brand Improv. Brand Improv uses professional actors to reenact real scenarios uncovered in fieldwork. This case study shows how Brand Improv powerfully brings to life new patient and caregiver insights in ADHD.
care community, including those pertaining to digital healthcare platforms and their expected impact on their profession, both positive and negative.
• What type of MR projects are best suited for online solutions?
• Case studies on different qualitative MR projects executed with iAdBoard: from payer research to competitive tracking
This paper proposes a predictive modelling and advanced analytics framework, leveraging machine learning and automation principles to assess past trends (tracking results) and deliver forward-looking insight at scale. The result is enhanced understanding, and the ability for sales and marketing teams to identify which actions will have the greatest impact on brand performance, leading to more actionable brand management.
Used properly, moderated far-ranging discussions can illicit deep and intimate responses, allowing us to capture those critical “moments of truth”. One of the key benefits in using MROCs is the ability to reach and engage with hard-to-reach respondents such as patients with rare diseases. In cases like this, MROCs provide an opportunity for patients with limited access to support groups to engage with each other, delivering richer insights as a result. During this paper will we demonstrate how, with careful set-up and management, online communities can be excellent methods of attaining an in-depth, meaningful understanding of patients with rare diseases.
The idea that a patient’s own cells can be reprogrammed to attack cancer cells or viruses can be used to repair faulty genes is a paradigm shift in medicine. However, a key challenge for all players and drug-makers in this field remains: significant cost of manufacturing, high price tags and the uncertainty around the market acceptance and uptake make it hard to forecast the potential of these innovative therapies. In this presentation, Fatma Aybegum Senkesen will introduce the audience to the basics of the science behind these therapies and also review how both conventional and innovative methods can be utilized to project the future of this innovative market.